WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 23, 1317-1327. Review Article ISSN 2277–7105

A REVIEW ARTICLE ON: ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT

Janhavi K. Bundele*, Ajit B. Tuwar and Megha T. Salve

Department of Pharmacy Shivajirao Pawar College of Pharmacy Pachegon –413725 Ahmednagar Maharashtra India.

Article Received on
17 October 2024,

Revised on 07 Nov. 2024,
Accepted on 27 Nov. 2024

DOI: 10.20959/wjpr202423-34836

***Corresponding Author**
Janhavi K. Bundele
Department of Pharmacy Shivajirao Pawar College of Pharmacy Pachegon – 413725 Ahmednagar Maharashtra India.

ABSTRACT

The rapid development of artificial intelligence (AI) and machine learning (ML) has significantly reshaped various industries, including pharmaceuticals. This review explores the application of AI and ML in drug discovery, highlighting their potential to enhance efficiency, accuracy, and cost-effectiveness throughout the drug development process. A systematic evaluation of recent literature reveals how these technologies facilitate drug design, molecular predictions, and regulatory procedures. Moreover, AI and ML are poised to reduce the need for extensive clinical trials through advanced simulations and predictive modeling. However, challenges such as data integration, regulatory hurdles, and a lack of skilled professionals remain barriers to widespread adoption. This paper discusses these challenges and outlines the future scope of AI and ML in revolutionizing drug discovery.

KEYWORDS: Introduction, Search Methodology and Article Selection, Results, Challenges of AI and ML integration in Drug Discovery and Development, Future Scope Of AI And ML Integration In Drug Discovery And Development, Real-World Example: AI in Drug Repurposing – The Case of COVID-19.

1. INTRODUCTION

Change is a constant aspect of life, and a primary goal of humanity is to harness these changes for beneficial outcomes particularly in medicine and pharmaceuticals. These fields aim to discover and create chemical compounds to alleviate physical and psychological suffering.[1] Historically, the production of drug products has adhered to a stringent regulatory

framework ensuring quality through rigorous testing of raw materials, intermediates, and final products.[2]

However, the pharmaceutical industry faces an imperative for innovation, particularly concerning mechanical processes, to streamline drug creation and to meet the rising demands for personalized medications.[3] Existing approaches often adhere to a "one size fits all" methodology, which necessitates novel pharmacological development processes tailored to individual patient biology and needs.[3]

AI is rapidly transforming the landscape of clinical research and pharmaceutical training. Currently, AI applications in the pharmaceutical industry include risk assessment, complication prevention during treatment, assistive technology during procedures, and elucidating the effects and applications of various substances.[5] The emergence of big data presents additional opportunities by allowing for extensive research and analysis, though current storage paradigms struggle under the vast amounts of data generated.[6-7]

The authors posit a need for a comprehensive review discussing the contributions of AI, machine learning, and big data to drug discovery and development, showcasing recent technological advancements and forecasting future implications for the industry.[9]

2. Search Methodology and Article Selection

To assess the current role of AI and ML in drug discovery, we conducted a systematic review of the literature. A comprehensive search was carried out across publicly accessible databases, focusing on studies published between January 2013 and October 2021. Keywords used in the search included “AI in drug discovery,” “machine learning,” “drug development,” and “pharmaceutical innovation.” The initial search identified 36 studies, which were further evaluated based on their relevance, methodologies, and contributions to the topic.

The reviewed studies provided insights into how AI and ML are being applied in various stages of drug discovery, from early-stage drug design to clinical trials and regulatory approval. The findings were then synthesized to form a cohesive understanding of the current landscape and potential future directions for these technologies.[10-22]

3. RESULTS

3.1 Advanced technologies in drug discovery

AI and ML are already making significant contributions to drug discovery, with numerous technologies in use today. Some of the most notable applications include:

- **In silico platforms**

One of the key innovations in drug discovery is the use of in silico platforms, such as the 'ADMET' model (absorption, distribution, metabolism, and excretion), which models pharmacokinetic endpoints for drug candidates. For example, Bayer employs an **in silico ADMET platform** that leverages machine learning to predict the pharmacokinetic properties of new molecules. While data collection for these models is intensive, machine learning algorithms enhance predictive performance, speeding up the early stages of drug discovery.[23]

- **Blockchain technology**

Blockchain is being explored for its potential to improve transparency and data integrity in pharmaceutical research. By decentralizing data storage, blockchain technology offers a secure and immutable record of research data, ensuring data integrity across the drug development lifecycle. However, widespread implementation remains hampered by high costs and technical challenges.[23]

- **3D Printing**

3D printing technology has introduced an innovative approach to pharmaceutical manufacturing. This technology enables on-demand production of drug formulations, offering the potential for more personalized treatment options. 3D printing also allows for customized dosing and more efficient manufacturing processes, contributing to the overall agility of the pharmaceutical industry.[23]



Fig. Advance technology in drug discovery.

3.2 Machine learning in drug discovery

Machine learning has become an indispensable tool in drug discovery. By analyzing large datasets of molecular and clinical data, machine learning algorithms can identify patterns and make predictions that traditional methods could not. Some key applications of ML in drug discovery include.[24-28]

- **Molecular property predictions**

ML models are increasingly used to predict molecular properties such as solubility, toxicity, and biological activity. These predictions are essential in identifying compounds that are likely to be effective and safe before they enter expensive and time-consuming clinical trials.[25]

- **Drug design**

Machine learning algorithms are used to design new drug molecules based on existing compounds. By learning from past data, ML can suggest novel compounds with similar or better efficacy and fewer side effects, speeding up the drug design process.[26]

- **Drug repurposing**

ML also plays a crucial role in ‘drug repurposing’ identifying existing drugs that can be used to treat new diseases. This approach is especially useful in public health emergencies, such as the COVID-19 pandemic, where time is of the essence.[27] For example, AI platforms were used to rapidly identify ‘Thioridazine’, an antipsychotic, as a potential COVID-19 treatment, demonstrating the value of ML in addressing urgent global health challenge.[28]



Fig. ML in drug discovery.

3.3 Artificial intelligence in drug discovery

AI is taking drug discovery to new heights, particularly in its ability to process and analyze vast datasets. AI systems combine multiple data sources, including clinical trial results, genomic data, and electronic health records, to make data-driven decisions. Some key applications of AI in drug discovery include.[29-31]

- **Predicting drug efficacy**

AI models are used to predict the likelihood that a drug will be effective for a specific disease or patient population. This allows pharmaceutical companies to focus their efforts on the most promising candidates, reducing the number of failed drugs in clinical trials.[29]

- **Personalized medicine**

AI enables the development of personalized drug treatments based on an individual's genetic and molecular profile. By analyzing large datasets of patient data, AI can identify which treatments are most likely to work for specific individuals, leading to more effective and safer therapies.[30]

- **Clinical trial optimization**

AI has also been used to optimize clinical trial design and patient recruitment. By analyzing patient data, AI can identify suitable candidates for trials, reducing recruitment time and increasing the likelihood of successful outcomes.[31]



Fig. AI in drug discovery.

4. Challenges of AI and ML Integration in Drug Discovery and Development

While the integration of AI and ML in drug discovery holds great promise, several challenges need to be addressed:

4.1 Data integration

The pharmaceutical industry generates large amounts of data, but this data often comes from different sources and formats. AI systems require high-quality, structured data to function effectively, and the integration of diverse datasets remains a major hurdle.[32]

4.2 Lack of skilled workforce

There is a growing demand for professionals who possess expertise in both data science and molecular biology. However, the supply of skilled workers is limited, making it difficult to implement AI-driven solutions across the pharmaceutical industry.[33]

4.3 Regulatory concerns

The pharmaceutical industry is highly regulated, and the use of AI raises concerns about data privacy, transparency, and accountability. Regulatory bodies need to develop frameworks that can accommodate the complexities of AI-driven drug discovery while ensuring patient safety.[34]

5. Future Scope of AI and ML Integration in Drug Discovery and Development

The future of AI and ML in drug discovery is promising. As these technologies continue to evolve, they have the potential to:

5.1 Reduce drug development costs

AI and ML can significantly cut costs by automating tasks that would otherwise require extensive human labor, such as data analysis and preclinical testing. This can lead to more affordable drug discovery and a faster time to market.[35-36]

5.2 Accelerate drug discovery timelines

With AI tools, pharmaceutical companies can accelerate the discovery process by predicting drug properties, optimizing clinical trial designs, and identifying promising drug candidates in a fraction of the time it would take using traditional methods.[37-39]

5.3 Enhance personalized medicine

AI's ability to process complex patient data will continue to enhance personalized medicine, enabling the development of treatments that are tailored to the genetic makeup and needs of individual patients.[40]

6. Real-World Example: AI in Drug Repurposing – The Case of COVID-19

In response to the COVID-19 pandemic, "Insilico Medicine" used its AI-powered platform to screen existing drugs for their potential to treat the virus. The AI system quickly identified "Thioridazine", an antipsychotic drug, as a potential candidate for repurposing.[41] This rapid identification of a promising treatment, achieved in just a few weeks, highlights the power of AI in addressing urgent health crises. Although Thioridazine was not ultimately approved for COVID-19 treatment, the case demonstrated the potential of AI to expedite drug discovery, particularly in emergency situations.[42]

7. CONCLUSION

In conclusion, AI and machine learning hold significant promise in transforming the drug discovery process by enhancing efficiency, reducing costs, and improving the accuracy of predictions. Despite the challenges in data integration and workforce development, the integration of AI into drug discovery is a step toward more personalized, efficient, and cost-effective healthcare solutions. Future developments in AI technology, coupled with improved regulatory frameworks, will likely unlock even greater potential for innovation in pharmaceutical research and drug development.

8. REFERENCES

1. Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. J Pharm Sci, 2015; 104(11): 3612–38. doi:10.1002/jps.24594.
2. Greenhill AT, Edmunds BR. A primer of artificial intelligence in medicine. Tech Innov Gastrointest Endosc, 2020; 22(2): 85–9. doi:10.1016/j.tgie.2019.150642.
3. Solanki P, Baldaniya D, Jogani D, et al. Artificial intelligence: new age of transformation in petroleum upstream. Pet Res, 2021. doi:10.1016/j.ptlrs.2021.07.002.
4. Kshirsagar A, Shah M. Anatomized study of security solutions for multimedia: deep learning enabled authentication, cryptography and information hiding. Adv Secur Solut Multimed, 2021. doi:10.1088/978-0-7503-3735-9CH7.
5. Anthony CC. Big data in medicine: the upcoming artificial intelligence. Prog Pediatr Cardiol, 2016; 43: 91–4. doi:10.1016/j.ppedcard.2016.08.021.
6. Göller AH, Kuhnke L, Montanari F, et al. Bayer's in silico ADMET platform: a journey of machine learning over the past two decades. Drug Discov Today, 2020; 25(9): 1702–9. doi:10.1016/j.drudis.2020.07.001.
7. Abu-Elezz I, Hassan A, Nazeemudeen A, et al. The benefits and threats of blockchain technology in healthcare: a scoping review. Int J Med Inform, 2020; 142: 104246. doi:10.1016/j.ijmedinf.2020.104246.
8. Park BJ, Choi HJ, Moon SJ, et al. Pharmaceutical applications of 3D printing technology: current understanding and future perspectives. J Pharm Investig, 2018; 49(6): 575–85. doi:10.1007/S40005-018-00414-Y.
9. Zimmerling A, Chen X. Bioprinting for combating infectious diseases. Bioprinting, 2020; 20: e00104. doi:10.1016/j.bprint.2020.e00104.
10. Elbadawi M, Gaisford S, Basit AW. Advanced machine-learning techniques in drug discovery. Drug Discov Today, 2021; 26(3): 769–77. doi:10.1016/j.drudis.2020.12.003.
11. Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data. Drug Discov Today, 2021; 26(4): 1040–52. doi:10.1016/j.drudis.2020.11.037.
12. Reker D. Practical considerations for active machine learning in drug discovery. Drug Discov Today Technol, 2019; 32-33: 73–9. doi:10.1016/j.ddtec.2020.06.001.
13. Margulis E, Dagan-Wiener A, Ives RS, et al. Intense bitterness of molecules: machine learning for expediting drug discovery. Comput Struct Biotechnol J, 2020; 19: 568–76. doi:10.1016/j.csbj.2020.12.030.

14. Raschka S, Kaufman B. Machine learning and AI-based approaches for bioactive ligand discovery and GPCR-ligand recognition. Methods, 2020; 180: 89–110. doi:10.1016/j.ymeth.2020.06.016.
15. Raschka S. Automated discovery of GPCR bioactive ligands. Curr Opin Struct Biol, 2019; 55: 17–24. doi:10.1016/j.sbi.2019.02.011.
16. Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. J Pharm Sci, 2015; 104(11): 3612–38. doi:10.1002/jps.24594.
17. Turki Turki, Taguchi YH. Machine learning algorithms for predicting drugs–tissues relationships. Expert Syst Appl, 2019; 127: 167–86. doi:10.1016/j.eswa.2019.02.013.
18. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Sci Adv, 2018; 4(7): eaap7885. doi:10.1126/sciadv.aap7885.
19. Taroni JN, Grayson PC, Hu Q, et al. MultiPLIER: a transfer learning framework for transcriptomics reveals systemic features of rare disease. Cell Syst, 2019; 8(5): 380–94 e4. doi:10.1016/j.cels.2019.04.003.
20. Li L, He X, Borgwardt K. Multi-target drug repositioning by bipartite block-wise sparse multi-task learning. BMC Syst Biol, 2018; 12(4): 55. doi:10.1186/s12918-018-0569-7.
21. Weng Y, Lin C, Zeng X, et al. Drug Target interaction prediction using multi-task learning and co-attention. In: Proceeding of the IEEE international conference bioinformatics and biomedicine BIBM, 2019; 528–33. doi:10.1109/BIBM47256.2019.8983254.
22. Han L, Zhang Y. Learning multi-level task groups in multi-task learning. Proceeding of the twenty-ninth AAAI conference on artificial intelligence, 2015. Available from https://www.aaai.org/ocs/index.php/AAAI/AAAI15/paper/view/9510.
23. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today, 2019; 24(3): 773–80. doi:10.1016/j.drudis.2018.11.014.
24. Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today, 2021; 26(1): 80–93. doi:10.1016/j.drudis.2020.10.010.
25. Dnyaneshwar K, Gaurav S, Debleena P, et al. Artificial intelligence in the pharmaceutical sector: current scene and future prospect. the future of pharmaceutical product development and research. Elsevier, 2020; 73–107. doi:10.1016/B978-0-12-814455-8.00003-7.
26. Cui RB, Zhu F. Ultrasound modified polysaccharides: a review of structure, physicochemical properties, biological activities and food applications. Trends Food Sci Technol, 2021; 107: 491–508. doi:10.1016/J.TIFS.2020.11.018.

27. Lusci A, Pollastri G, Baldi P. Deep architectures and deep learning in chemoinformatics: the prediction of aqueous solubility for drug-like molecules. J Chem Inf Model, 2013; 53(7): 1563–75. doi:10.1021/ci400187y.
28. Polykovskiy D, Zhebrak A, Vetrov D, et al. Entangled Conditional adversarial autoencoder for de novo drug discovery. Mol Pharm, 2018; 15(10): 4398–405. doi:10.1021/acs.molpharmaceut.8b00839.
29. Daynac M, Cortes-Cabrera A, Prieto JM. Application of artificial intelligence to the prediction of the antimicrobial activity of essential oils. Evid Based Complement Altern Med, 2015; 561024: 2015. doi:10.1155/2015/561024.
30. Pu L, Naderi M, Liu T, et al. eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacol Toxicol, 2019; 20(1): 2. doi:10.1186/s40360-018-0282-6.
31. Kadurin I, Rothwell S, Ferron L, et al. Investigation of the proteolytic cleavage of α 2 δ subunits: a mechanistic switch from nhibition to activation of voltage-gated calcium channels? Biophys J, 2017; 112(3): 244a. doi:10.1016/j.bpj.2016.11.1335.
32. Maram Y, Hamdy H. The role of artificial intelligence in revealing the results of the interaction of biological materials with each other or with chemicals. Mater Today Proc, 2021; 45: 4954–9. doi:10.1016/j.matpr.2021.01.387.
33. Unterthiner T, Mayr A, Klambauer G, et al. Toxicity Prediction using deep learning, 2015; 1-10. Available from: https://arxiv.org/abs/1503.01445v1.
34. Avdagic Z, Begic Fazlic L, Konjicija S. Optimized detection of tar content in the manufacturing process using adaptive neuro-fuzzy inference systems. Stud Health Technol Inform, 2009; 150: 615–19.
35. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol, 2019; 37(9): 1038–40. doi:10.1038/s41587-019-0224-x.
36. Lee H, Kim W. Comparison of target features for predicting drug-target interactions by deep neural network based on large-scale drug-induced transcriptome data. Pharmaceutics, 2019; 11(8): 377. doi:10.3390/pharmaceutics11080377.
37. Putin E, Asadulaev A, Ivanenkov Y, et al. Reinforced adversarial neural computer for de novo molecular design. J Chem Inf Model, 2018; 58(6): 1194–204. doi:10.1021/acs.jcim.7b00690.
38. Henstock PV. Artificial intelligence for pharma: time for internal investment. Trends Pharmacol Sci, 2019; 40(8): 543–6. doi:10.1016/j.tips.2019.05.003.

39. Chan HCS, Shan H, Dahoun T, et al. Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci, 2019; 40(8): 592–604. doi:10.1016/j.tips.2019.06.004.
40. Wang LL, Ding JJ, Pan L, et al. Artificial intelligence facilitates drug design in the big data era. Chemom Intell Lab Syst, 2019; 194: 103850. doi:10.1016/j.chemolab.2019.103850.
41. Kshirsagar A. Bio-remediation: use of nature in a technical way to fight pollution for a long run. ResearchGate, 2018. doi:10.13140/RG.2.2.26906.70088.
42. Artificial intelligence and machine learning in drug discovery and development by Veer Patel, Manan Shah in Intelligent Medicine.